# US 2022/0031744 A1 · Protein l for activation and expansion of chimeric antigen receptor-modified immune cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031744 A1
- Document ID: US20220031744A1
- Status: Published application
- Kind: A1
- Application number: 17/277,396
- Filed: 2019-09-19
- Published: 2022-02-03
- Earliest claimed: 2018-09-19
- Assignees: FUJIFILM Cellular Dynamics, Inc.
- Applicants: FUJIFILM Cellular Dynamics, Inc.
- Inventors: Maksym VODYANYK; Ethan McLEOD; Xin ZHANG; Wen Bo WANG
- Web page: https://patentgrep.com/patent/US20220031744A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 38/1709: {from mammals}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4211: {CD19 or B4}
- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70521: {CD28, CD152}
- C12N 5/0636: {T lymphocytes}
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C12N 2500/02: Atmosphere, e.g. low oxygen conditions
- C12N 2500/38: Vitamins
- C12N 2501/125: Stem cell factor [SCF], c-kit ligand [KL]
- C12N 2501/145: Thrombopoietin [TPO]
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2501/2307: Interleukin-7 (IL-7)
- C12N 2501/2315: Interleukin-15 (IL-15)
- C12N 2501/26: Flt-3 ligand (CD135L, flk-2 ligand)
- C12N 2501/42: Notch; Delta; Jagged; Serrate
- C12N 2501/515: CD3, T-cell receptor complex
- C12N 2506/45: from artificially induced pluripotent stem cells
- C12N 2510/00: Genetically modified cells
- C12N 2533/50: Proteins
- C12N 2533/52: Fibronectin; Laminin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are methods for the activation and expansion of T cells. Further provided are methods for the use of the T cells for therapy.

## Claims

### Claim 1

An in vitro method for activation and/or expansion of CAR-modified immune cells comprising:
(a) obtaining a starting population of CAR-modified immune cells; and
(b) culturing said population of CAR-modified immune cells in the presence of Protein L for a sufficient period of time to produce a population of activated and/or expanded CAR-modified immune cells.

### Claim 2 (depends on 1)

The method of claim 1, wherein the Protein L is coated on a culture surface.

### Claim 3 (depends on 2)

The method of claim 2, wherein the culture surface is a culture plate, culture flask, microcarrier, microparticle, hydrogel particle, or culture bag.

### Claim 4 (depends on 2)

The method of claim 2, wherein the culturing is performed in the absence of anti-CD3 antibody and/or antigen-specific target cells.

### Claim 5 (depends on 1)

The method of claim 1, wherein the CAR-modified immune cells are T cells, NK cells, dendritic cells, and/or macrophages.

### Claim 6 (depends on 5)

The method of claim 5, wherein the T cells are CD8+ T cells, CD4+ T cells, αβ T cells or γδ T cells.

### Claim 7 (depends on 6)

The method of claim 6, wherein the method further comprises selecting for CD8+ T cells.

### Claim 8 (depends on 1)

The method of claim 1, wherein the CAR-modified immune cells are allogeneic.

### Claim 9 (depends on 1)

The method of claim 1, wherein the CAR-modified immune cells are autologous.

### Claim 10 (depends on 1)

The method of claim 1, wherein the CAR-modified immune cells are derived from pluripotent stem cells (PSCs).

### Claim 11 (depends on 10)

The method of claim 10, wherein the PSCs are induced pluripotent stem cells (iPSCs).

### Claim 12 (depends on 11)

The method of claim 11, wherein the iPSCs are reprogrammed from blood cells.

### Claim 13 (depends on 11)

The method of claim 11, wherein the iPSCs are reprogrammed from T cells.

### Claim 14 (depends on 11)

The method of claim 11, wherein the iPSCs are episomally reprogrammed.

### Claim 15 (depends on 1)

The method of claim 1, wherein the CAR-modified immune cells are derived from primary peripheral blood mononuclear cells (PBMCs) or primary hematopoietic stem cells.

### Claim 16 (depends on 10, 11, 12, 13, 14)

The method of any one of claims 10-14, wherein the iPSCs are differentiated to CD34+ progenitors through cytokine-directed differentiation.

### Claim 17 (depends on 10, 11, 12, 13, 14)

The method of any one of claims 10-14, wherein the iPSCs are differentiated to CD34+ progenitors through forward programming.

### Claim 18 (depends on 1)

The method of claim 1, wherein the CAR comprises an antigen-binding domain selected from the group consisting of F(ab′)2, Fab′, Fab, Fv, and scFv.

### Claim 19 (depends on 1)

The method of claim 1, wherein the CAR comprises CD28 co-stimulatory and CD3 signaling domains.

### Claim 20 (depends on 2)

The method of claim 2, wherein the culture surface is further coated with retronectin, fibronectin, or VCAM1.

### Claim 21 (depends on 20)

The method of claim 20, wherein the retronectin is at a concentration of 0.1-1 μg/cm2.

### Claim 22 (depends on 20)

The method of claim 20, wherein the retronectin is at a concentration of 0.5 μg/cm2.

### Claim 23 (depends on 2, 20)

The method of claim 2 or 20, wherein the culture surface is further coated with Notch ligand DLL4.

### Claim 24 (depends on 23)

The method of claim 23, wherein the DLL4 is at a concentration of 0.1-1 μg/cm2.

### Claim 25 (depends on 23)

The method of claim 23, wherein the DLL4 is at a concentration of 0.5 μg/cm2.

### Claim 26 (depends on 1)

The method of claim 1, wherein the culturing is performed in the presence of IL-2 and/or IL-15.

### Claim 27 (depends on 26)

The method of claim 26, wherein the IL-12 and/or IL-15 are present at a concentration of 5-15 ng/mL.

### Claim 28 (depends on 26)

The method of claim 26, wherein the IL-12 and/or IL-15 are present at a concentration of 10 ng/mL.

### Claim 29 (depends on 1)

The method of claim 1, wherein the culturing is under hypoxic conditions.

### Claim 30 (depends on 29)

The method of claim 29, wherein the hypoxic conditions comprise 5% oxygen.

### Claim 31 (depends on 1)

The method of claim 1, wherein the sufficient period of time is 8-12 days.

### Claim 32 (depends on 31)

The method of claim 31, wherein the sufficient period of time is 8, 9, or 10 days.

### Claim 33 (depends on 1)

The method of claim 1, wherein the culturing is in medium comprising SCF, TPO, FLT3L, and/or IL-7.

### Claim 34 (depends on 33)

The method of claim 33, wherein the SCF, TPO, FLT3L, and/or IL-7 are at a concentration of 50 ng/mL.

### Claim 35 (depends on 33)

The method of claim 33, wherein the medium further comprises nicotinamide.

### Claim 36 (depends on 1)

The method of claim 1, wherein the method results in the selective expansion of CAR-modified immune cells as compared to non-CAR-modified immune cells.

### Claim 37 (depends on 36)

The method of claim 36, wherein at least 40% or 50% of the expanded population of CAR-modified immune cells are CAR-modified immune cells.

### Claim 38 (depends on 5)

The method of claim 5, wherein the expanded population of CAR-modified T cells comprises at least 25% CD3+CD8+ CAR-modified T cells.

### Claim 39 (depends on 5)

The method of claim 5, wherein the expanded population of CAR-modified T cells comprises 2-3 fold higher cytotoxic activity as compared to anti-CD3 expanded CAR-modified T cells.

### Claim 40 (depends on 5)

The method of claim 5, wherein the expanded population of CAR-modified T cells comprises increased IFNγ and/or TNFα levels compared to anti-CD3 expanded CAR-modified T cells.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

A population of activated and/or expanded CAR-modified immune cells produced according to the methods of any one of claims 1-40.

### Claim 42 (depends on 41)

A pharmaceutical composition comprising the population of activated and/or expanded CAR-modified immune cells of claim 41 and a pharmaceutically acceptable carrier.

### Claim 43 (depends on 41)

A method of treating a cancer in a subject comprising administering a therapeutically effective amount of the activated and/or expanded CAR-modified immune cells of claim 41 to the subject.

### Claim 44 (depends on 43)

The method of claim 43, wherein the activated and/or expanded CAR-modified immune cells are allogenic.

### Claim 45 (depends on 43)

The method of claim 43, wherein the activated and/or expanded CAR-modified immune cells are autologous.

### Claim 46 (depends on 43)

The method of claim 43, further comprising administering at least a second therapeutic agent.

### Claim 47 (depends on 46)

The method of claim 46, wherein the at least a second therapeutic agent is a therapeutically effective amount of an immunomodulatory or an immunosuppressive agent.

### Claim 48 (depends on 47)

The method of claim 47, wherein the at least second therapeutic agent is selected from the group consisting of chemotherapy, radiotherapy, and immunotherapy.

### Claim 49 (depends on 46)

The method of claim 46, wherein the activated and/or expanded CAR-modified immune cells, and/or the at least a second therapeutic agent are administered intravenously, intraperitoneally, intratracheally, intratumorally, intramuscularly, endoscopically, intralesionally, percutaneously, subcutaneously, regionally, by direct injection, or by perfusion.

### Claim 50 (depends on 41, 42)

Use of a composition of claim 41 or 42 for the treatment of cancer in subject in need thereof.

### Claim 51

A composition comprising CAR-modified immune cells and Protein L.

### Claim 52 (depends on 51)

The composition of claim 51, wherein the Protein L is coated on a culture surface.

### Claim 53 (depends on 51)

The composition of claim 51, further comprising retronectin.
